265 related articles for article (PubMed ID: 32471953)
41. A Truncated Granulocyte Colony-stimulating Factor Receptor (G-CSFR) Inhibits Apoptosis Induced by Neutrophil Elastase G185R Mutant: IMPLICATION FOR UNDERSTANDING CSF3R GENE MUTATIONS IN SEVERE CONGENITAL NEUTROPENIA.
Qiu Y; Zhang Y; Hu N; Dong F
J Biol Chem; 2017 Feb; 292(8):3496-3505. PubMed ID: 28073911
[TBL] [Abstract][Full Text] [Related]
42. [Roles of CEBPA mutation and expression abnormality in acute myeloid leukemia - review].
Wang LM; Xiao HW; Huang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1256-60. PubMed ID: 23114160
[TBL] [Abstract][Full Text] [Related]
43. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
44. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
45. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
46. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
[TBL] [Abstract][Full Text] [Related]
47. RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.
Romanova EI; Zubritskiy AV; Lioznova AV; Ogunleye AJ; Golotin VA; Guts AA; Lennartsson A; Demidov ON; Medvedeva YA
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232714
[TBL] [Abstract][Full Text] [Related]
48. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
49. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
50. Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations.
Lance A; Druhan LJ; Vestal CG; Steuerwald NM; Hamilton A; Smith M; Price A; Tjaden E; Fox AN; Avalos BR
Leukemia; 2020 Feb; 34(2):369-379. PubMed ID: 31462738
[TBL] [Abstract][Full Text] [Related]
51. Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.
Nitulescu II; Meyer SC; Wen QJ; Crispino JD; Lemieux ME; Levine RL; Pelish HE; Shair MD
EBioMedicine; 2017 Dec; 26():112-125. PubMed ID: 29239838
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
[TBL] [Abstract][Full Text] [Related]
53. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
54. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
55. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1.
Lynch JT; Cockerill MJ; Hitchin JR; Wiseman DH; Somervaille TC
Anal Biochem; 2013 Nov; 442(1):104-6. PubMed ID: 23911524
[TBL] [Abstract][Full Text] [Related]
56. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
[TBL] [Abstract][Full Text] [Related]
57. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
[TBL] [Abstract][Full Text] [Related]
58. [Analysis of
Cui M; Li QY; Lu XZ; Chao HY; Cai XH; Liu J; Hua HY; Wu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1019-1025. PubMed ID: 37551471
[TBL] [Abstract][Full Text] [Related]
59. Mutations in the bZip region of the CEBPA gene: A novel prognostic factor in patients with acute myeloid leukemia.
Rivera JC; Nuñez D; Millar E; Ramirez K; Chandía M; Aguayo C
Int J Lab Hematol; 2023 Dec; 45(6):833-838. PubMed ID: 37621152
[TBL] [Abstract][Full Text] [Related]
60. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
